Audit Report Tv)
Report No: 0713308726
Version 1

Product Service

2.5 Audit Trails
Description of activities covered during the Audit, key element summary for each audited subsystem.

2.5.1 Management and Quality Management System

Subsystem Management - Quality Management System
Audit trail Martin Szepannek / George Pavlov / Gabriele Mousset / Honorata Donnermair
records of
Area(s) visited Location # 10578 (all Tasks)

(location, e.g., Location # 90464 (Task 9/11)
site visited) For more details related to audit location and time refer to chapter 2.2 of this report.

Audit criteria
according to
audit plan

"Management: QMS Planning, Implementation, Changes and Quality Manual (MDSAP Chapter 1, Task 1, Site: 10578);
(DIN)(EN) ISO 13485 - 4.1.1, 4.1.2, 4.1.3, 4.2.2, 4.1.4, 5.4.2 + (DIN)(EN) ISO 9001 - 4.3, 4.4, 6.1, 6.3, 7.5.1, 8.4 + MDSAP - Australia - TG(MD)R Sch3 P1
1.4(4) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.1, 5.6 + MDSAP - Japan - MHLW MO169: 5-1, 5-2, 5-3, 5-4, 7, 14; [Old3: 5, 7, 14] + MDSAP - USA - 21
CFR 820.20 + MDR - Article 10.8 1, 10.9 §1S2, 10.9 3 (a,e); Annex IX2.1@, 2.2 $2 (ct, c3); Annex XI 6.4 + MDD - Annex Il (3.1,3.2)"
"Management: Management Representative (MDSAP Chapter 1, Task 2, Site: 10578);

(DIN)(EN) ISO 13485 - 5.5.2 + (DIN)(EN) ISO 9001 - 5,3 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b)(ii)_ + MDSAP - Brazil - RDC ANVISA 16/2013:
2.2.5 +MDSAP - Japan - MHLW MO169: 16 + MDSAP - USA - 21 CFR 820.20(b) + MDR - Article 15 + MDD - Annex II (3.2)"

"Management: Quality Policy and Quality Objectives (MDSAP Chapter 1, Task 3, Site: 10578);

(DIN)(EN) ISO 13485 - 5.3, 5.4.1 + (DIN)(EN) ISO 9001 - 5.2, 6.2 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(a) + MDSAP - Brazil - RDC ANVISA
16/2013: 2.2.1 + MDSAP - Japan - MHLW MO169: 12, 13 + MDSAP - USA - 21CFR 820.20(a) + MDR - Annex IX 2.2.9[2 (a); Annex XI6.2972  +MDD -
Annex II (3.2), Annex V (3.2), Annex VI (3.2)"

"Management: Organizational Structure, Responsibility, Authority, Resources (MDSAP Chapter 1, Task 4, Site: 10578);

(DIN)(EN) ISO 13485 - 5.1, 5.5.1, 5.5.2, 6.1,6.2+ (DIN)(EN) ISO 9001 - 5.1, 5.3, 7.1.1, 7.1.2, 7.2, 7.3 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b) +
MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.2, 2.2.3. 2.2.4, 2.3 + MDSAP - Japan - MHLW MO169: 10, 15, 16, 21, 22,23 + MDSAP - USA - 21 CFR
820.20(b), 820.25 + MDR - Annex IX 2.1@@, 2.2 {2 (a, b1); Annex X14 &6.2 2; Article 10(16) + MDD - Annex II (3.1, 3.2), Annex V (3.1, 3.2), Annex VI
(3.1)"

"Management: Extent Of Outsourcing (MDSAP Chapter 1, Task 5, Site: 10578);

(DIN)(EN) ISO 13485 - 4.1.5, 4.2.1 + (DIN)(EN) ISO 9001 - 4.4, 8.4, 7.5.1 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - RDC
ANVISA 16/2013: 2.5 + MDSAP - Japan - MHLW MO169: 5-5, 6; [Old: 5,6] + MDSAP - USA - 21 CFR 820.50 + MDR - Article 10.9 13 (d); Annex IX 2.2 [2
(a, b3); Annex XI 6.2 ]2, 12 11; Article 10 (15) + MDD - Annex II (3.2 (b, d, e)), Annex V (3.2(b, ¢, d), Annex VI (3.2), [EK-MED 3.09B16]"

"Management: Personnel Competency and Training (MDSAP Chapter 1, Task 6, Site: 10578);

(DIN)(EN) ISO 13485 - 4.2.1, 6.2 + (DIN)(EN) ISO 9001 - 7.2, 7.3, 7.5.1 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.3, 2.2.4, 2.3. + MDSAP - Japan -
MHLW M0169: 6, 22, 23 + MDSAP - USA - 21 CFR 820.20(b)(2), 820.25 + MDR - Annex IX 2.1 {[1, 2.2 2 (a), Article 15, [MPDG §83] + MDD - Annex II (3.1,
3.2), Annex V (3.1, 3.2), Annex VI (3.1)"

"Management: Risk Management Planning and Review (MDSAP Chapter 1, Task 7, Site: 10578);

(DIN)(EN) ISO 13485 - 4.1.2 (b), 7.1 + (DIN)(EN) ISO 9001 - 4.4, 8.1, 8.4 + MDSAP - Australia - TG(MD)R Sch1 P12 + MDSAP - Brazil - RDC ANVISA
16/2013: 2.4 + MDSAP - Japan - MO169: 5-2.1.2, 26; [Old: 26] + MDSAP - USA - 21 CFR 820.30(g) + MDR - Article 10.9 [3 (e);Annex IX 2.2 [2 (c3); Annex
1 (2,3,4,5,8) & Il (5) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"

"Management: Document and Record Controls (MDSAP Chapter 1, Task 8, Site: 10578);

(DIN)(EN) ISO 13485 - 4.1.4, 4.2.1, 4.2.4, 4.2.5 + (DIN)(EN) ISO 9001 - 4.4, 7.5.1, 7.5.2, 7.5.3, 8.4 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(4), 1.9;
Reg 5.10 +MDSAP - Brazil - RDC ANVISA 16/2013: 3.1 + MDSAP - Japan - MO169: 5-4, 6, 8, 9, 67, 68; [Old: 5, 6, 8, 9] + MDSAP - USA - 21 CFR 820.40,
820.180 + MDR - Article 10.8 1, 10.9 11 $2; Annex IX 2.2 2 (a,c); Annex XI 12 1; Article 10, 11, 12, 22, 27, 29, 31, 51, 52, [MDCG 2019-16, 2021-19],
[MPDG § 5)] + MDD - Annex Il (3.2), Annex V (3.2), Annex VI (3.1, 3.2) [EK-MED 3.09 B20]"

"Management: Management Reviews (MDSAP Chapter 1, Task 9, Site: 10578);

(DIN)(EN) ISO 13485 - 5,6 + (DIN)(EN) ISO 9001 - 9,3 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b)\iii)(f) + MDSAP - Brazil - RDC ANVISA 16/2013:
2.2.6 +MDSAP - Japan - MO169: 18, 19, 20 + MDSAP - USA - 21 CFR820.20(c) + MDR - Article 10.8 1 S2; Annex IX 2.2 [2 (c8) + MDD - Annex II (3.1),
Annex V (3.1), Annex VI (3.1)"

"Management: Distribution of Devices with Appropriate Marketing Authorization (MDSAP Chapter 1, Task 10, Site: 10578);

(DIN)(EN) ISO 13485 - 4.1.1, 4.2.1, 5.2, 7.2.1, 7.2.3 + (DIN)(EN) ISO 9001 - 4.4, 5.2.1, 7.5.1, 8.2.1, 8.2.2, 8.4 + MDR - Article 10.9 [3 (a); Annex IX 2.2 2
(ct), Article 19, Annex IV, Annex IX ch _III.6, Annex XI 2, 6 + MDD - Annex II (3.2)"

"Management: Top Management Commitment to Quality (MDSAP Chapter 1, Task 11, Site: 10578);

(DIN)(EN) ISO 13485 - 4.1.1, 4.1.4, 5.1, 5.5.3 + (DIN)(EN) ISO 9001 - 4.4, 5.1.1, 7.4, 8.4 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.1, 2.2.1 + MDSAP -
Japan - MO169: 5-1, 5-4, 10, 17; [Old: 5, 10, 17]_ + MDSAP - USA - 21 CFR 820.20(a), 820.5 + MDR - Article 10.9 3 (c) + MDD - Annex Il (2, 3.1)"

Brief description
of processes or
activities
evaluated to
demonstrate
what was
audited related
to the listed key
QMS documents
and records
reviewed below
considering
inputs, outputs,
and measures

ID: 31505

General Info (GM

>16.000 employees word wide

3,4 Mio EUR net sales

Liibeck HQ (DWAG) (Moislinger Allee) , Revalstr. (production and logistics)
Safety and Medical Business (Medical Business around 2/3 of annual revenue)
Organised in therapeuticel Busienss Units (BU Therapy, Patient Monitroing, Workplace Infrastraucture, Hospital
Consumables and Accessories, Global Services)

Production Sites Worldwide

DWAG = Dragerwerk AG

2240 Employees in Medical Business

895 in R+D

630 n Production

1530 in Moislinger allee

710 in RevalstraRe (Production)

Changes since last year:

BU Therapie:

EVITA some products in phase out

New product M11.3 (CO? sensor)

EVITA group Changes release 2.0 and prep 3.0
Qxylog 3000 Plus, SW change to v 1.10

Savina 300 new SW Version 5.02.01

Savina Color EoP June 2023

ATLAN family (A 300/A350), new SW features, v.2.0 (Cyber) and bugfixes, all MDSAP countries
Perseus A500 CE mark MDR since 04/2023

Zeus IE, SW update 2.03, only Australian and Canada

Drager One P

ICM (intregrated Care Manager), SW14.0.0

New product: lung protective ventilation analytics, non medical SW

SPV smart pilot view; v 3.03, currently TD review stage

Core new product, Infinity to STC and back, SW 1.0 + Converter Service, currently TD review stage

Doc No: MED_T_09.50 Revision: 12 — released Effective: 28 May 2021 Page 5 of 107
